CCR2 and myeloid sarcoma: There is ongoing debate as to whether this CCR2 mediated chemotaxis is as important in MS as it is in animal disease models [74,75,76], nonetheless, the potential for a therapeutic CCR2 targeting antibody is under investigation [77].